Among patients with a tumor proportion score of ≥50% for PD-L1 and lacking sensitizing EGFR or ALK mutations, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice [4]. This evidence concerns the gene EGFR and neoplasm.